InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023

InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023

Investor Presentation to be held at 9:15 a.m. Eastern Time

ROCHESTER HILLS, Mich.–(BUSINESS WIRE)–
InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will present at the Sidoti Micro-Cap Virtual Investor Conference at 9:15 a.m. ET on Thursday, May 11, 2023.

A webcast of the presentation will be available on the Company’s website at https://ir.infusystem.com. A replay of the presentation will be available following the event.

Management is scheduled to host virtual one-on-one meetings throughout the day. Investors interested in arranging one-on-one meetings should contact your conference representative. Conversely, you may also call or email Lytham Partners at 602-889-9700, or [email protected].

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, objectives and prospects, future operating or financial performance and guidance and expected new business relationships and the terms thereof. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives, our ability to enter into definitive agreements for new business relationships on expected terms or at all, the uncertain impact of the COVID-19 pandemic, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

Joe Dorame, Joe Diaz & Robert Blum

Lytham Partners, LLC

602-889-9700

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: General Health Medical Devices Health Practice Management Medical Supplies

MEDIA:

Logo
Logo

Ryder Declares Quarterly Cash Dividend

Ryder Declares Quarterly Cash Dividend

Company Pays Dividend for 187th Consecutive Quarter

MIAMI–(BUSINESS WIRE)–
The Board of Directors of Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions, declared a regular quarterly cash dividend of $0.62 per share of common stock to be paid on June 16, 2023 to shareholders of record on May 22, 2023.

This is Ryder’s 187th consecutive quarterly cash dividend – marking more than 46 years of uninterrupted dividend payments.

About Ryder System, Inc.

Ryder System, Inc. (NYSE: R) is a leading logistics and transportation company. It provides supply chain, dedicated transportation, and fleet management solutions, including warehousing and distribution, e-commerce fulfillment, last-mile delivery, managed transportation, professional drivers, freight brokerage, full-service leasing, maintenance, commercial truck rental, and used vehicle sales to some of the world’s most-recognized brands. Ryder provides services throughout the United States, Mexico, and Canada. In addition, Ryder manages nearly 260,000 commercial vehicles and operates approximately 300 warehouses encompassing more than 95 million square feet. Ryder is regularly recognized for its industry-leading practices in third-party logistics, technology-driven innovations, commercial vehicle maintenance, environmental stewardship, corporate social responsibility, world-class safety and security programs, military veteran recruitment initiatives, and the hiring of a diverse workforce. www.ryder.com

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

ryder-financial

Amy Federman, (305) 500-4989, [email protected]

Calene Candela, (305) 500-4053, [email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Automotive Manufacturing Automotive Manufacturing Other Transport Trucking Rail Transport Other Automotive General Automotive Logistics/Supply Chain Management Fleet Management

MEDIA:

Logo
Logo

Alcon Announces Results of 2023 Annual General Meeting

Alcon Announces Results of 2023 Annual General Meeting

  • Shareholders approve dividend of CHF 0.21 per share
  • Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election
  • Shareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation Report in an advisory vote, as well as the Board and Executive Committee compensation in separate binding votes

GENEVA–(BUSINESS WIRE)–
Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM).

A total of 321,168,907 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 12,846,756.28, were represented at today’s AGM.

Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who all stood for re-election, namely Lynn Bleil, Raquel Bono, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a term of one year.

In addition, shareholders re-elected Thomas Glanzmann, Karen May, Scott Maw and Ines Pöschel to form the Compensation Committee for a period of one year.

Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2022 financial year.

In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2024 Annual General Meeting, and the Executive Committee for 2024. Shareholders also accepted the 2022 Compensation Report, in a non-binding, consultative vote.

Shareholders also approved the Board of Directors’ proposal for the amendments of the Articles of Incorporation of Alcon Inc. implementing the requirements of the reform of Swiss corporate law that came into force on January 1, 2023 and taking into account current best corporate governance practice.

“It was a pleasure to host our first in-person AGM in Lausanne, and I am thankful for our shareholders’ high level of engagement and participation,” said F. Michael Ball, Chair of the Board of Directors. “With the trust and support of our shareholders, we will continue to live our purpose of helping the world See Brilliantly.”

Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2022.

Shareholders also approved that a gross dividend of CHF 0.21 per dividend-bearing share be declared, and that, after appropriation of the proposed dividend, the remaining amount of available earnings be carried forward.

Pricewaterhouse Coopers SA, Geneva, was re-elected as statutory auditors for the 2023 financial year. Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2024 AGM.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on

Facebook

LinkedIn

Investor Relations

Dan Cravens

Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

[email protected]

Media Relations

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 615 2501 (Fort Worth)

[email protected]

KEYWORDS: Texas Europe Switzerland United States North America

INDUSTRY KEYWORDS: Research Pharmaceutical Optical Medical Devices Clinical Trials Science Surgery Biotechnology Medical Supplies Other Science Health Diabetes

MEDIA:

Logo
Logo

Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation

Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation

SOMERSET, N.J.–(BUSINESS WIRE)–
Catalent, Inc. (“Catalent”) (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. TRC’s offer price is approximately 4.43% lower than the $44.94 closing price of Catalent’s common stock on April 24, 2023, the last trading day prior to the date of the mini-tender offer (April 25, 2023).

Catalent does not endorse TRC’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to this unsolicited mini-tender offer because the offer is at a price below the current market price of Catalent’s common stock and is subject to numerous other conditions.

Catalent is not affiliated or associated in any way with TRC, its mini-tender offer or the offer documentation. TRC has made similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire not more than 5 percent of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (the “SEC”) that are designed to protect investors. As a result, mini-tender offers do not provide investors with the same level of protection as provided by larger tender offers under United States federal securities laws.

The SEC has issued “Tips for Investors” regarding mini-tender offers, cautioning investors that some bidders, in making the offers at below-market prices, are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s advisory may be found on the SEC website at http://www.sec.gov/investor/pubs/minitend.htm.

Catalent urges stockholders to obtain current market quotations for their shares of common stock, to consult their broker or financial advisor, and to exercise caution with respect to TRC’s mini-tender offer.

Catalent recommends that stockholders who have not responded to TRC’s mini-tender offer take no action. Catalent stockholders who have already tendered their shares may withdraw their shares by providing the written notice described in TRC’s offering documents prior to the expiration of the mini-tender offer, currently scheduled for 12:01 a.m., New York City time, on May 24, 2023, unless the offer is extended or earlier terminated.

Catalent urges brokers, dealers and other market participants to review the SEC’s recommendations to broker-dealers in these circumstances, which can be found on the SEC website at http://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Catalent requests that a copy of this news release be included with all distributions of materials relating to TRC’s mini-tender offer.

About Catalent

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

[email protected]

Media Contact:

Chris Halling

+44 (0)7580 041073

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Professional Services Health Finance General Health Pharmaceutical Biotechnology

MEDIA:

Royal Gold Presenting at the BofA Securities Global Metals, Mining & Steel Conference

Royal Gold Presenting at the BofA Securities Global Metals, Mining & Steel Conference

DENVER–(BUSINESS WIRE)–Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that management will present at the BofA Securities Global Metals, Mining & Steel Conference in Barcelona, Spain. Bill Heissenbuttel, President and CEO, will address conference participants on Wednesday, May 17, at 2:40 p.m. CEST (8:40 a.m. EDT; 6:40 a.m. MDT) in a fireside chat lasting 20 minutes. The presentation will be live streamed, and a webcast replay will be available within 24 hours after the conclusion of the live event and may be accessed on the Company’s website at www.royalgold.com, under Investors/Events & Presentations.

Corporate Profile

Royal Gold is a precious metals stream and royalty company engaged in the acquisition and management of precious metal streams, royalties and similar production-based interests. As of March 31, 2023, the Company owned interests on 182 properties on five continents, including interests on 40 producing mines and 19 development stage projects. Royal Gold is publicly traded on the Nasdaq Global Select Market under the symbol “RGLD.” The Company’s website is located at www.royalgold.com.

Alistair Baker

Vice President Investor Relations and Business Development

(720) 554-6995

KEYWORDS: Colorado Spain North America United States Europe Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo

Tredegar Board Declares Quarterly Dividend

Tredegar Board Declares Quarterly Dividend

RICHMOND, Va.–(BUSINESS WIRE)–
The board of directors of Tredegar Corporation (NYSE:TG) declared a quarterly dividend of thirteen cents ($0.13) per share on the company’s common stock. The dividend is payable on July 3, 2023 to shareholders of record at the close of business on June 19, 2023.

Tredegar Corporation is an industrial manufacturer with three primary businesses: custom aluminum extrusions for the North American building & construction, automotive and specialty end-use markets; surface protection films for high-technology applications in the global electronics industry; and specialized polyester films primarily for the Latin American flexible packaging market. Tredegar had 2022 sales of $939 million. With approximately 2,200 employees, the Company operates manufacturing facilities in North America, South America, and Asia.

Neill Bellamy

Phone: 804/330-1211

E-mail: [email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Construction & Property Packaging Machine Tools, Metalworking & Metallurgy Technology Automotive Manufacturing Other Construction & Property Manufacturing Other Technology

MEDIA:

Logo
Logo

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 05, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-533, ORIC-114, ORIC-944 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2023, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]



DT Midstream Announces Quarterly Dividend

DETROIT, May 05, 2023 (GLOBE NEWSWIRE) — The Board of Directors of DT Midstream, Inc. (NYSE: DTM) has declared a $0.69 per share dividend on its common stock payable Jul. 15, 2023 to shareholders of record at the close of business Jun. 19, 2023.

About DT Midstream

DT Midstream (NYSE: DTM) is an owner, operator and developer of natural gas interstate and intrastate pipelines, storage and gathering systems, compression, treatment and surface facilities. The company transports clean natural gas for utilities, power plants, marketers, large industrial customers and energy producers across the Southern, Northeastern and Midwestern United States and Canada. The Detroit-based company offers a comprehensive, wellhead-to-market array of services, including natural gas transportation, storage and gathering. DT Midstream is transitioning towards net zero greenhouse gas emissions by 2050, including a plan of achieving 30% of its carbon emissions reduction by 2030. For more information, please visit the DT Midstream website at www.dtmidstream.com.



Investor Relations

Todd Lohrmann, DT Midstream, 313.774.2424
[email protected]

Firsthand Technology Value Fund Discloses Preliminary NAV of $4.10 Per Share as of March 31, 2023

Firsthand Technology Value Fund Discloses Preliminary NAV of $4.10 Per Share as of March 31, 2023

Top Holdings Include IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital

SAN JOSE, Calif.–(BUSINESS WIRE)–
Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of March 31, 2023, was $4.10. The Fund further announced that its top five holdings as of March 31, 2023, were IntraOp Medical, Hera Systems, Revasum, Wrightspeed, and EQX Capital.

1.

IntraOp Medical Corp. is the manufacturer of the Mobetron, a medical device that is used to deliver electron-based radiation to cancer patients. As of March 31, 2023, the Fund’s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 50.7% of the Fund’s preliminary net assets.

 

2.

Hera Systems, Inc. is developing micro satellites with imaging and communication capabilities for launch into low Earth orbit. As of March 31, 2023, the Fund’s investment in Hera consisted of preferred stock plus debt securities and warrants to purchase additional shares and represented approximately 31.8% of the Fund’s preliminary net assets.

 

3.

Revasum, Inc. (ASX: RVS) is a provider of chemical-mechanical planarization (CMP) and grinding tools to the semiconductor industry. As of March 31, 2023, the Fund’s investment in Revasum consisted of common stock equivalents (CDIs) and represented approximately 22.6% of the Fund’s preliminary net assets.

 

4.

Wrightspeed, Inc. is a supplier of electric drivetrains for heavy-duty trucks. As of March 31, 2023, the Fund’s investment in Wrightspeed consisted of preferred and common stock plus debt securities and warrants to purchase additional shares and represented approximately 14.3% of the Fund’s preliminary net assets.

 

5.

EQX Capital, Inc. provides equipment financing solutions to technology companies and their customers. As of March 31, 2023, the Fund’s investment in EQX consisted of preferred and common stock and represented approximately 1.7% of the Fund’s preliminary net assets. 

The Fund’s preliminary net assets as of March 31, 2023, include cash and cash equivalents of approximately $0.12 per share. Preliminary total investments as of March 31, 2023, were $35.4 million, or approximately $5.13 per share. As of March 31, 2023, the Fund’s top five holdings constituted 121.1% of the Fund’s preliminary net assets, and 96.7% of our preliminary total investments. The Fund’s NAV for March 31, 2023, as well as complete financial statements and a detailed schedule of investments, will be made available with the Fund’s quarterly report filing on Form 10-Q in May 2023.

About Firsthand Technology Value Fund

Firsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies. More information about the Fund and its holdings can be found online at www.firsthandtvf.com.

The Fund is a non-diversified, closed-end investment company that elected to be treated as a business development company under the Investment Company Act of 1940. The Fund’s investment objective is to seek long-term growth of capital. Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies. An investment in the Fund involves substantial risks, some of which are highlighted below. Please see the Fund’s public filings for more information about fees, expenses and risk. Past investment results do not provide any assurances about future results.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined under the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to materially differ from the Fund’s historical experience and its present expectations or projections indicated in any forward-looking statement. These risks include, but are not limited to, changes in economic and political conditions, regulatory and legal changes, technology and cleantech industry risk, valuation risk, non-diversification risk, interest rate risk, tax risk, and other risks discussed in the Fund’s filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Fund undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Fund’s investment objectives will be attained. We acknowledge that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as us.

Phil Mosakowski

Firsthand Capital Management, Inc.

(408) 624-9526

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo

GAN Schedules 2023 First Quarter Financial Results Conference Call for May 10, 2023

GAN Schedules 2023 First Quarter Financial Results Conference Call for May 10, 2023

IRVINE, Calif.–(BUSINESS WIRE)–
GAN Limited (the “Company” or “GAN”) (NASDAQ: GAN), a leading North American B2B technology provider of real money internet gaming solutions and a leading International B2C operator of Internet sports betting, today announced that it will release financial results for the first quarter ended March 31, 2023, after market close on Wednesday, May 10, 2023.

The Company will host a conference call to discuss these financial results at 4:30 PM ET that same day.

Conference Call Details

Date/Time:

Wednesday, May 10, 2023, at 4:30 PM ET

Webcast:

https://www.webcast-eqs.com/ganlimited20230510

U.S. Toll-Free Dial In:

(888) 437-3179

International Dial In:

(862) 298-0702

To access the call, please dial in approximately ten minutes before the start of the call. An accompanying slide presentation will be available in PDF format on the “Results and Presentations” page of the Company’s website.

About GAN Limited

GAN is a leading business-to-business supplier of internet gaming software-as-a-service solutions predominantly to the U.S. land-based casino industry. Coolbet, a division of GAN, is a market-leading operator of proprietary online sports betting technology with market leadership positions in select European and Latin American markets. GAN has developed a proprietary internet gaming enterprise software system, GameSTACK™, which it licenses to land-based casino operators as a turnkey technology solution for regulated real money internet gaming, encompassing internet gaming, internet sports gaming, and virtual Simulated Gaming. Additional information about GAN can be found online at www.GAN.com.

Investor:

GAN

Robert Shore

Vice President, IR and Capital Markets

(610) 812-3519

[email protected]

Alpha IR Group

Ryan Coleman or Davis Snyder

(312) 445-2870

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Entertainment Technology Online Software Internet Electronic Games Casino/Gaming

MEDIA: